WEgovy Real World Assessment of Weight Loss in Korea

Sponsor
Novo Nordisk A/S
Study ID
NCT07280221
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Semaglutide injection will be self-administered once weekly subcutaneously.

Study Details

This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.

Key Dates

Start date
Nov 10, 2025
Status verified
Dec 2025
Primary completion
Oct 31, 2027
Completion
Oct 31, 2027

Study Design

Enrollment
500 participants (estimated)

Arms

  • Arm: Once weekly Wegovy
    Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.

Primary Outcome Measure

Percentage change in body weight [ Time Frame: From baseline (week 0) to 24 weeks ]

Related Studies